

LISTING OF THE CLAIMS:

Please amend the prior claims and add the new claims in the application as shown in the listing of claims below.

1-68. Canceled.

69. (Currently Amended): A method of delivering a substance into an intradermal compartment of a human subject's skin, said method comprising administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between 0.3 mm and 2 mm, such that delivery of the substance occurs at a depth between 0.3 mm and 2 mm, wherein ~~the a dosage of the substance for achieving a systemic distribution of the substance biological effect is reduced by at least 10% compared to when the substance is delivered to a subcutaneous compartment of the human subject's skin.~~

70. (Currently Amended): The method of claim 69, wherein ~~the systemic distribution biological effect is results in~~ a therapeutic or diagnostic effect.

71. (Previously Presented): The method of claim 69 wherein the administering comprises inserting the needle so that the substance is deposited at a depth of at least about 0.3 mm below the surface of the human subject's skin to no more than about 2 mm below the surface of the human subject's skin.

72. (Previously Presented): The method of claim 69 wherein the administering comprises inserting the needle into the skin so that the substance is deposited at a depth of at least about 0.3 mm and no more than about 2 mm.

73. (Previously Presented): The method of claim 69 wherein the substance is administered over a time period of not more than ten minutes.

74. (Previously Presented): The method of claim 69 wherein the substance is administered at a rate between 1 nL/min. and 200 mL/ min.

75. (Previously Presented): The method of claim 69 wherein the needle(s) are inserted substantially perpendicularly to the skin.
76. (Canceled): ~~The method of claim 69 wherein the dosage is reduced by at least 10% compared to subcutaneous injection.~~
77. (Previously Presented): The method of claim 69 wherein the dosage is reduced by at least 20%.
78. (Previously Presented): The method of claim 69 wherein the dosage is reduced by at least 30%.
79. (Previously Presented): The method of claim 69 wherein the substance is a peptide, protein or nucleic acid.
80. (Previously Presented): The method of claim 69 wherein the substance is a diagnostic or therapeutic substance.
81. (Previously Presented): The method of claim 69 wherein the substance is hydrophobic.
82. (Previously Presented): The method of claim 69 wherein the substance is hydrophilic.
83. (Previously Presented): The method of claim 69 wherein the substance is a hormone.
84. (Previously Presented): The method of claim 69 wherein the substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.
85. (Currently Amended): A method of delivering a substance into an intradermal compartment of a human subject's skin, said method comprising injecting or infusing the substance intradermally through one or more microneedles having a length sufficient to penetrate the intradermal compartment and an outlet at a depth within the intradermal compartment wherein ~~the a~~ dosage of the substance for achieving a systemic distribution of the substance biological effect is reduced by at least 10% compared to when the substance is delivered to a subcutaneous compartment of the human subject's skin.
86. (Previously Presented): The method of claim 85 wherein the length of the microneedle(s) is from about 0.5 mm to about 1.7 mm.

87. (Previously Presented): The method of claim 85 wherein the microneedle is a 30 to 34 gauge needle.
88. (Previously Presented): The method of claim 85 wherein the microneedle has an outlet depth of from 0 to 1 mm.
89. (Previously Presented): The method of claim 85 wherein the microneedle is configured in a delivery device which positions the microneedle perpendicular to skin surface.
90. (Previously Presented): The method of claim 85 wherein the microneedle is contained in an array of microneedles.
91. (Previously Presented): The method of claim 90 wherein the array comprises 3 microneedles.
92. (Previously Presented): The method of claim 90 wherein the array comprises 6 microneedles.
93. (Previously Presented): The method of claim 85 wherein the substance is administered over a time period of not more than ten minutes.
94. (Previously Presented): The method of claim 85 wherein the substance is administered at a rate between 1 nL/min. and 200 mL/min.
95. (Previously Presented): The method of claim 85 wherein the microneedle(s) are inserted substantially perpendicularly to the skin.
96. (Canceled): ~~The method of claim 85 wherein the dosage is reduced by at least 10% compared to subcutaneous injection.~~
97. (Previously Presented): The method of claim 85 wherein the dosage is reduced by at least 20%.
98. (Previously Presented): The method of claim 85 wherein the dosage is reduced by at least 30%.

99. (Previously Presented): The method of claim 85 wherein the substance is a peptide, protein, or nucleic acid.

100. (Previously Presented): The method of claim 85 wherein the substance is a hormone.

101. (Previously Presented): The method of claim 85 wherein the substance is hydrophobic.

102. (Previously Presented): The method of claim 85 wherein the substance is hydrophilic.

103. (Previously Presented): The method of claim 85 wherein the substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.

104. (Previously Presented): The method of claim 69 or 85 wherein the substance is used for the treatment of a symptom of a pathological condition.